Duchenne Muscular Dystrophy (DMD) Treatment Market Size, Share, Opportunities, And Trends By Tests (Blood Test, Molecular, Genetic Testing, Electromyography, Muscle Biopsy), By Treatment (Physical Therapy, Orthopedic Devices, Steroids, Others), And By Geography - Forecasts From 2025 To 2030

Duchenne Muscular Dystrophy (DMD) Treatment Market Size:

The Duchenne muscular dystrophy (DMD) treatment market is expected to grow from US$5,415.322 million in 2025 to US$10,954.230 million in 2030, at a CAGR of 15.13%.

Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder caused by the mutation of the DMD gene, which is responsible for making a protein called dystrophin causing progressive muscle degeneration. At present, there is no cure for the disease, certain research strategies are being worked upon, however, the treatment is provided for the mitigation of disease symptoms.

The growing incidence of rare diseases, rising R&D investments, and growing adoption of genetic testing worldwide are some of the major drivers driving the growth of the Duchenne muscular dystrophy (DMD) treatment market during the forecast period. Furthermore, growing awareness regarding self-care and self-management resulting in early disease detection will help in disease management in an efficient manner leading to sustainable market growth in the near future and beyond. The prevalence of Duchenne and Becker muscular dystrophy (DBMD) among Non-Hispanic blacks was lower than the prevalence among Hispanics and Non-Hispanic whites (Centers for Disease Control and Prevention, CDC). Thus, owing to high disease prevalence, North America and Europe are expected to hold a significant market share globally.

This research study examines the current market trends related to demand, supply, and sales, in addition to recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases, and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top-down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the Duchenne muscular dystrophy (DMD) treatment value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics for providing a faster and more efficient understanding of the Duchenne muscular dystrophy (DMD) treatment market.

Major industry players profiled as part of the report are Pfizer Inc., Sarepta Therapeutics, Inc., ReveraGen BioPharma, Inc., PTC Therapeutics, and NIPPON SHINYAKU CO., LTD. among others.

Duchenne Muscular Dystrophy (DMD) Treatment Market Scope:

Report Metric	Details
Duchenne Muscular Dystrophy (DMD) Treatment Market Size in 2025	US$5,415.322 million
Duchenne Muscular Dystrophy (DMD) Treatment Market Size in 2030	US$10,954.230 million
Growth Rate	CAGR of 15.13%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Million
Segmentation	Tests Treatment Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in Duchenne Muscular Dystrophy (DMD) Treatment Market	Pfizer Inc. Sarepta Therapeutics, Inc. ReveraGen BioPharma, Inc. PTC Therapeutics NIPPON SHINYAKU CO., LTD.
Customization Scope	Free report customization with purchase

 

The Duchenne muscular dystrophy (DMD) treatment market is analyzed into the following segments:

By Tests

---